RxDoctor Payments Data

Hector Yordan, MD

General Practice · Mayaguez, PRNPI 1619154283

Payments from drug & device makers

$2,597in general payments, 2019–2025

Across 40 payments — averaging $64.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$1K
  • Johnson & Johnson$350
  • BD$182
  • AstraZeneca$125
  • PBG Puerto Rico LLC$119
  • Merck$86
  • plus $245 from 5 others

What the payments were for

  • Travel & lodging$1,16345%
  • Food & beverage$1,43455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,597 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,114
Medicare patients
13
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol66$60,204
XareltoRivaroxaban50$50,797
EliquisApixaban49$34,721
JardianceEmpagliflozin18$17,931
JanuviaSitagliptin Phosphate14$13,609
Mesalamine12$10,166
Breo ElliptaFluticasone/Vilanterol20$8,219
SynthroidLevothyroxine Sodium71$6,024
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm51$5,922
Losartan Potassium273$3,046
Candesartan Cilexetil22$2,892
Atorvastatin Calcium271$2,562
Gabapentin245$2,480
Humulin NInsulin Nph Human Isophane29$2,397
Glimepiride119$2,221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$125$60,20466 claims
Johnson & JohnsonXarelto$350$50,79750 claims
MerckJanuvia$86$13,60914 claims
Sanofi-aventis U.S. LLCLantus$57$1,99221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →